Dr Hughes

Barnett RN et al. Multiphasic screening by laboratory tests – An overview of the problem. Am J Clin Pathol 1970;54(3):483-92. Abstract

King MC et al. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312(11):1091-2. Abstract

Dr Robson

Garber J et al. OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS01-09.

Litton JK et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: Results of a phase II study. Oncologist 2023;28(10):845-55. Abstract

Meyer E et al. TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort. San Antonio Breast Cancer Symposium 2024;Abstract RF3-01.

Tung NM et al. TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. ASCO 2024;Abstract 1021.